Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CVAC Stock Forecast 2026-2027
$4.66
Current Price
$1.05B
Market Cap
Buy 1
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to CVAC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CVAC Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+49.4%
1 Year Change
+3.1%
Year-to-Date Change
-18.5%
From 52W High of $5.72
+88.3%
From 52W Low of $2.48
📊 TOP ANALYST CALLS
Did CVAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CureVac is one of their latest high-conviction picks.
Latest CVAC Stock Price Targets & Analyst Predictions
CVAC has shown a year-to-date change of 3.1% and a 1-year change of 49.4%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CVAC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CVAC Analyst Ratings
1
Buy
3
Hold
0
Sell
CVAC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $4.66
Latest CVAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CVAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 26, 2025 | UBS | Eliana Merle | Neutral | Downgrade | $5.50 |
| Jun 13, 2025 | Jefferies | Roger Song | Hold | Downgrade | $5.00 |
| May 28, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $10.00 |
| Apr 30, 2025 | UBS | Eliana Merle | Buy | Maintains | $12.00 |
| Feb 14, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $16.00 |
| Sep 16, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $16.00 |
| Aug 16, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $16.00 |
| Jul 3, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $18.00 |
| Apr 25, 2024 | Leerink Partners | Mani Foroohar | Market Perform | Downgrade | $4.00 |
| Apr 5, 2024 | Guggenheim | Evan Wang | Neutral | Reiterates | $N/A |
| Aug 21, 2023 | B of A Securities | Geoff Meacham | Underperform | Maintains | $8.00 |
| Jun 8, 2023 | SVB Securities | Mani Foroohar | Outperform | Initiates | $13.00 |
| Apr 26, 2023 | JMP Securities | Roy Buchanan | Outperform | Maintains | $24.00 |
| Jan 19, 2023 | UBS | Eliana Merle | Buy | Upgrade | $18.00 |
| Jan 9, 2023 | Jefferies | Eun Yang | Buy | Upgrade | $N/A |
| Nov 17, 2022 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $34.00 |
| Apr 22, 2022 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $37.00 |
| Jan 21, 2022 | B of A Securities | Geoff Meacham | Underperform | Downgrade | $20.00 |
| Dec 31, 2021 | Deutsche Bank | Hold | Initiates | $N/A | |
| Oct 22, 2021 | Deutsche Bank | Hold | Initiates | $N/A |
CureVac N.V. (CVAC) Competitors
The following stocks are similar to CureVac based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CureVac N.V. (CVAC) Financial Data
CureVac N.V. has a market capitalization of $1.05B with a P/E ratio of 7.0x. The company generates $83.87M in trailing twelve-month revenue with a 182.1% profit margin.
Revenue growth is -89.0% quarter-over-quarter, while maintaining an operating margin of +573.0% and return on equity of +23.3%.
Valuation Metrics
Market Cap
$1.05B
Enterprise Value
$547.94M
P/E Ratio
7.0x
PEG Ratio
-0.4x
Price/Sales
14.8x
Growth & Margins
Revenue Growth (YoY)
-89.0%
Gross Margin
+99.3%
Operating Margin
+573.0%
Net Margin
+182.1%
EPS Growth
-19.2%
Financial Health
Cash/Price Ratio
+49.4%
Current Ratio
3.7x
Debt/Equity
4.0x
ROE
+23.3%
ROA
+20.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CureVac N.V. (CVAC) Business Model
About CureVac N.V.
What They Do
Develops transformative mRNA-based medicines and vaccines.
Business Model
CureVac operates by utilizing its proprietary mRNA technology platform to develop vaccines and therapeutics for infectious diseases, cancer, and genetic disorders. The company generates revenue through partnerships with pharmaceutical companies and by advancing its products through clinical trials, particularly in response to global health needs.
Additional Information
Founded in 2000 and based in Tübingen, Germany, CureVac has made significant contributions to vaccine development, especially during the COVID-19 pandemic. Its collaborations with larger pharmaceutical firms enhance its market position and underline its role in the evolving landscape of precision medicine and healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
825
CEO
Dr. Alexander Zehnder M.B.A., M.D.
Country
Germany
IPO Year
2020
Website
www.curevac.comCureVac N.V. (CVAC) Latest News & Analysis
Latest News
Quick Summary
BioNTech has satisfied the minimum condition for its offer by tendering 184,071,410 shares of CureVac, or about 81.74% of its outstanding shares. A subsequent offering period is open until December 18, 2025.
Why It Matters
The high tender rate of CureVac shares indicates strong investor confidence in BioNTech's acquisition, potentially boosting BioNTech's market position and future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CureVac N.V. will hold an Extraordinary General Meeting of Shareholders on November 25, 2025, at 8:00 AM EST, featuring key company executives.
Why It Matters
CureVac's shareholder call indicates potential developments and strategic decisions, impacting stock performance and investor sentiment. Key management presence suggests significant updates are forthcoming.
Source: Seeking Alpha
Market Sentiment:
Neutral
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
4 months ago
Quick Summary
BioNTech received German clearance for its acquisition of CureVac, with an exchange offer running from Oct 21 to Dec 3, 2025. CureVac has €416.1M in cash, supporting operations through 2028.
Why It Matters
Clearance for BioNTech's acquisition of CureVac and clinical advancements signal strong growth potential, while robust cash reserves enhance financial stability, boosting investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
CureVac N.V. announced the voting results from its Extraordinary General Meeting held on November 25, 2025. The company focuses on developing mRNA-based medicines.
Why It Matters
CureVac's EGM results could indicate strategic shifts or governance changes, potentially impacting its stock performance and future development in mRNA therapies.
Source: Accesswire
Market Sentiment:
Neutral
CureVac: The Hidden Value Of The mRNA Wallet
6 months ago
Quick Summary
CureVac (CVAC) specializes in mRNA drugs for oncology and vaccines, with over 25 years of research and nearly 1,000 patents, emphasizing its strong intellectual property portfolio.
Why It Matters
CureVac's extensive mRNA patent portfolio and long research history enhance its market position, potentially increasing future revenue through successful drug development and innovations.
Source: Seeking Alpha
Market Sentiment:
Positive
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
8 months ago
Quick Summary
CureVac reported strong Q2 2025 results, with €392.7 million in cash. BioNTech plans to acquire CureVac, resolving patent disputes. EMA cleared CTA for a new cancer therapy.
Why It Matters
CureVac's merger with BioNTech enhances mRNA capabilities, resolving legal disputes boosts stability, and strong cash reserves support ongoing and future projects, signaling growth potential.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About CVAC Stock
What is CureVac N.V.'s (CVAC) stock forecast for 2026?
Analyst forecasts for CureVac N.V. (CVAC) are not currently available. The stock is trading at $4.66.
Is CVAC stock a good investment in 2026?
According to current analyst ratings, CVAC has 1 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CVAC stock?
Price predictions from Wall Street analysts for CVAC are not currently available. The stock is trading at $4.66.
What is CureVac N.V.'s business model?
CureVac operates by utilizing its proprietary mRNA technology platform to develop vaccines and therapeutics for infectious diseases, cancer, and genetic disorders. The company generates revenue through partnerships with pharmaceutical companies and by advancing its products through clinical trials, particularly in response to global health needs.
What is the highest forecasted price for CVAC CureVac N.V.?
Price targets from Wall Street analysts for CVAC are not currently available. The stock is trading at $4.66.
What is the lowest forecasted price for CVAC CureVac N.V.?
Price targets from Wall Street analysts for CVAC are not currently available. The stock is trading at $4.66.
What is the overall CVAC consensus from analysts for CureVac N.V.?
The overall analyst consensus for CVAC is neutral. Out of 8 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 0 as Sell.
How accurate are CVAC stock price projections?
Stock price projections, including those for CureVac N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 16, 2026 4:03 AM UTC